Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease

Oncogene volume 18, pages 2755–2761 (1999)Cite this article

Abstract

Identification of prostate cancers at high risk of progression is difficult and a better understanding of how peptide growth factors influence cellular function might be useful. Fibroblast growth factors (FGFs) have been implicated in prostate cancer development. FGF8 was identified in the Shionogi mouse mammary carcinoma SC-3 cell line as an androgen-induced mitogen. We tested if FGF8 was over-expressed in human prostate cancer and if its expression correlated with clinical data and outcome. One hundred and six cases of prostate cancer and ten cases of BPH were examined. In situ hybridization was employed to detect FGF8 mRNA expression, which was identified within the malignant prostatic epithelium in 85/106 (80.2%) cases. Increased expression of FGF8 correlated significantly with higher Gleason scores (P=0.0004) and advanced tumour stage (P=0.0016). Using immunohistochemistry, we confirmed over-expression of the FGF8b isoform. Men with tumours which expressed high levels of FGF8 had worse survival (P=0.034), although FGF8 mRNA was not able to provide additional prognostic information in a multivariate analysis. Additionally, FGF8 expression was shown to persist in androgen independent prostate cancer. Using a range of normal adult tissues, FGF8 expression was restricted to neurones and the germinal epithelium in addition to the prostate. In vitro studies demonstrated that in the presence of neutralizing antibody to FGF8b there was significant inhibition of prostate cancer cell growth, confirming the biological significance of FGF8 in prostate carcinogenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Crossley PH, Minowada G, MacArthur CA and Martin GR. . 1996 Cell 84: 127–136.

    Article  CAS  Google Scholar 

  • Gemel J, Gorry M, Erhlich GD and MacArthur CA. . 1996 Genomics 35: 253–257.

    Article  CAS  Google Scholar 

  • Ghosh AK, Shankar DB, Shackleford GM, Wu K, T'Ang A, Miller GJ, Zheng J and Roy-Burman P. . 1996 Cell, Growth & Differ. 7: 1425–1435.

  • Ittman M and Mansukhani A. . 1997 J. Urol. 157: 351–356.

  • Lee SM, Danielian PS, Fritzsch B and McMahon AP. . 1997 Development 124: 959–969.

  • Leung HY, Dickson C, Robson CN and Neal DE. . 1996 Oncogene 12: 1833–1835.

  • Leung HY, Mehta P, Gray L, Collins AT, Robson CN and Neal DE. . 1997 Oncogene 15: 1115–1120.

    Article  CAS  Google Scholar 

  • MacArthur CA, Lawshe A, Xu J, Santos-Ocamp S, Heikinheimo M, Chellaiah AT and Ornitz DM. . 1995a Development 121: 3603–3613.

  • MacArthur CA, Lawshe A, Shankar DB, Heikinheimo M and Shackleford GM. . 1995b Cell Growth & Differ. 6: 817–825.

  • Mason I. . 1994 Cell 78: 547–552.

    Article  CAS  Google Scholar 

  • Myers RL, Chedid M, Tronick SR and Chiu I-M. . 1995 Oncogene 11: 785–789.

  • Office For National Statistics. . 1996 Population and Health Monitor DH2 96/2.

  • Payson RA, Wu J, Liu Y and Chiu I-M. . 1996 Oncogene 13: 47–53.

  • Rudra-Ganguly N, Zheng J, Hoang AT and Roy-Burman P. . 1998 Oncogene 16: 1487–1492.

    Article  CAS  Google Scholar 

  • Schmitt JF, Hearn MT and Risbridger GP. . 1996 J. Steroid Biochem. Mol. Biol. 57: 173–178.

  • Smallwood PM, Munoz-Sanguan I, Tong P, Macke JP, Hendry SHC, Gilbert DJ, Copeland NG, Jenkins NA and Nathans J. . 1996 Proc. Natl. Acad. Sci. USA 93: 9850–9857.

  • Susuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB and Bova GS. . 1998 Cancer Res. 58: 204–209.

  • Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H and Matsumoto K. . 1992 Proc. Natl. Acad. Sci. USA 89: 8928–8932.

  • Tanaka A, Miyamoto K, Matsuo H, Matsumoto K, Yoshida H. . 1995 FEBS Lett. 363: 226–230.

  • Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M and Fukayama M. . 1998 Cancer Res. 58: 2053–2056.

  • Yazidi IE and Boilly-Marer Y. . 1995 Anticancer Res. 15: 783–790.

Download references

Acknowledgements

This study was funded partly by The Cancer Research Campaign; Trevor J Dorkin is supported by The Royal College of Surgeons of England and the NHS R&D programme.

Author information

Authors and Affiliations

  1. School of Surgical Sciences, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK

    Trevor J Dorkin, David E Neal & Hing Y Leung

  2. Department of Pathology, Freeman Hospital, Freeman Road, Newcastle upon Tyne, NE7 7DN, UK

    Mary C Robinson & Colin Marsh

  3. Department of Urology, University Hospital, Malmo, S-205 02, Sweden

    Anders Bjartell

Authors
  1. Trevor J Dorkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary C Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Colin Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anders Bjartell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David E Neal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hing Y Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dorkin, T., Robinson, M., Marsh, C. et al. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 18, 2755–2761 (1999). https://doi.org/10.1038/sj.onc.1202624

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202624

Keywords

This article is cited by

Search

Advanced search

Quick links